Inactive Instrument

ImmunoPrecise Antibodies Ltd. Toronto S.E.

Equities

IPA

CA45257F2008

Pharmaceuticals

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Transcript : ImmunoPrecise Antibodies Ltd., Q3 2024 Earnings Call, Mar 14, 2024
ImmunoPrecise Antibodies Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2024 CI
Certain Warrants of ImmunoPrecise Antibodies Ltd. are subject to a Lock-Up Agreement Ending on 6-MAR-2024. CI
Certain Stock Options of ImmunoPrecise Antibodies Ltd. are subject to a Lock-Up Agreement Ending on 6-MAR-2024. CI
Certain Common Shares of ImmunoPrecise Antibodies Ltd. are subject to a Lock-Up Agreement Ending on 6-MAR-2024. CI
ImmunoPrecise Antibodies Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2023 CI
Transcript : ImmunoPrecise Antibodies Ltd., Q2 2024 Earnings Call, Dec 14, 2023
Top Premarket Gainers MT
Private Payrolls Increased Less Than Expected in November as US Equity Futures Rise Pre-Bell MT
Jobs Data in Focus as Exchange-Traded Funds, Equity Futures Lean Higher Pre-Bell Wednesday MT
Top Premarket Decliners MT
ImmunoPrecise Antibodies Plans Underwritten Offering of Common Stock; Shares Fall Pre-Bell MT
ImmunoPrecise Antibodies Ltd. Announces Board Changes CI
ImmunoPrecise Antibodies Develops the Lensai's Integrated Intelligence Platform Powered by Hyft Technology CI
ImmunoPrecise Antibodies Names Kristin Taylor Interim Finance Chief MT
ImmunoPrecise Antibodies Announces CFO Transition CI
Transcript : ImmunoPrecise Antibodies Ltd., Q1 2024 Earnings Call, Sep 14, 2023
ImmunoPrecise Antibodies Ltd. Reports Earnings Results for the First Quarter Ended July 31, 2023 CI
ImmunoPrecise Antibodies Ltd. Announces Board Changes CI
ImmunoPrecise Antibodies Ltd Issues a Response to Ingalls & Snyder LLC Filing CI
Transcript : ImmunoPrecise Antibodies Ltd. - Special Call
ImmunoPrecise Antibodies Ltd. Reports Earnings Results for the Full Year Ended April 30, 2023 CI
ImmunoPrecise Antibodies Ltd. Auditor Raises 'Going Concern' Doubt CI
Ingalls & Snyder Proposes a Change to the Members of ImmunoPrecise Antibodies’ Board CI
Transcript : ImmunoPrecise Antibodies Ltd., Q4 2023 Earnings Call, Jul 07, 2023
Chart ImmunoPrecise Antibodies Ltd.
More charts
ImmunoPrecise Antibodies Ltd. is a Canada-based biotherapeutic research and technology company. The Company is a supplier of custom antibody discovery services. The Company offers species-agnostic advancements, such as the B cell Select single-cell interrogation technology, DeepDisplay custom phage libraries, as well as the Abthena bispecific program- platforms. It leverages systems biology, multi-omics modelling and complex artificial intelligence systems to support its technologies in bio platform-based antibody discovery. It offers a selection of antibodies, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma licensing for research purposes. Its services include specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to support its business partners. The Company offers support to its partners, including rapid multi-omic analysis, customized project design, and others.
More about the company